465 related articles for article (PubMed ID: 1724437)
1. Fifteen-year experience in Hodgkin's disease: role of combined modality treatment and splenectomy in the incidence of secondary acute leukemia.
Zinzani PL; Fiacchini M; Mazza P; Gherlinzoni F; Bocchia M; Tura S
Haematologica; 1991; 76(4):305-10. PubMed ID: 1724437
[TBL] [Abstract][Full Text] [Related]
2. The risk of acute leukemia in patients treated for Hodgkin's disease is significantly higher aft [see bined modality programs than after chemotherapy alone and is correlated with the extent of radiotherapy and type and duration of chemotherapy: a case-control study.
Brusamolino E; Anselmo AP; Klersy C; Santoro M; Orlandi E; Pagnucco G; Lunghi F; Maurizi-Enrici R; Baroni CD; Lazzarino M; Mandelli F; Bernasconi C
Haematologica; 1998 Sep; 83(9):812-23. PubMed ID: 9825578
[TBL] [Abstract][Full Text] [Related]
3. Hodgkin's disease and the risk of acute leukemia in successfully treated patients.
Valagussa P; Bonadonna G
Haematologica; 1998 Sep; 83(9):769-70. PubMed ID: 9825571
[No Abstract] [Full Text] [Related]
4. Analysis of the risk of solid tumor following Hodgkin's disease.
Maurizi Enrici R; Anselmo AP; Osti MF; Santoro M; Tombolini V; Mandelli F; Biagini C
Haematologica; 1997; 82(1):57-63. PubMed ID: 9107084
[TBL] [Abstract][Full Text] [Related]
5. Bulky mediastinal Hodgkin's disease: results of a combined modality approach (ABVD/MOPP alternating chemotherapy plus radiation therapy).
De Lena M; Ditonno P; Lorusso V; Timurian A; Pellecchia A; Brandi M; Berardi F; Marzullo F
Haematologica; 1993; 78(4):230-5. PubMed ID: 7507457
[TBL] [Abstract][Full Text] [Related]
6. [Combined-modality therapy for 150 cases of early-stage Hodgkin's lymphoma].
Niu Y; Shi YK; He XH; Feng FY; Zhou LQ; Gu DZ
Zhonghua Zhong Liu Za Zhi; 2008 Aug; 30(8):630-4. PubMed ID: 19102946
[TBL] [Abstract][Full Text] [Related]
7. [Second neoplasms as a late complication of the treatment of Hodgkin's disease].
Morales MD; González FA; Villegas A; del Potro E; Díaz Mediavilla J; Martínez R; Alvarez A; Colomé JA
Sangre (Barc); 1992 Dec; 37(6):429-33. PubMed ID: 1293793
[TBL] [Abstract][Full Text] [Related]
8. Hodgkin's disease: controversies and challenges for the future.
Tura S; Canellos G; Goldstone A; Longo D; McMillan A; Urba W; Zinzani PL
Haematologica; 1991; 76(4):263-79. PubMed ID: 1724436
[No Abstract] [Full Text] [Related]
9. Hodgkin's disease: summary of twenty years' experience.
Mazza P; Bocchia M; Zinzani PL; Fiacchini M; Gherlinzoni F; Bandini G; Bendandi M; Frezza GP; Neri S; Barbieri E
Haematologica; 1992; 77(6):487-93. PubMed ID: 1283856
[TBL] [Abstract][Full Text] [Related]
10. Splenectomy and the increasing risk of secondary acute leukemia in Hodgkin's disease.
Tura S; Fiacchini M; Zinzani PL; Brusamolino E; Gobbi PG
J Clin Oncol; 1993 May; 11(5):925-30. PubMed ID: 8487056
[TBL] [Abstract][Full Text] [Related]
11. Hodgkin's disease. A historical perspective.
Avilés A; Díaz-Maqueo JC; Torras V; Ayala JR; Cortés HD
Arch Invest Med (Mex); 1991; 22(1):27-33. PubMed ID: 1726450
[TBL] [Abstract][Full Text] [Related]
12. [Outcome of 70 patients diagnosed with Hodgkin's disease after first-line and salvage treatment: experience at one center].
Arranz R; Gil-Fernández JJ; Muñoz E; Acevedo A; Sobrino MP; Fernández-Rañada JM
Sangre (Barc); 1998 Jun; 43(3):179-84. PubMed ID: 9741222
[TBL] [Abstract][Full Text] [Related]
13. High-dose BEAM chemotherapy with autologous haemopoietic stem cell transplantation for Hodgkin's disease is unlikely to be associated with a major increased risk of secondary MDS/AML.
Harrison CN; Gregory W; Hudson GV; Devereux S; Goldstone AH; Hancock B; Winfield D; MacMillan AK; Hoskin P; Newland AC; Milligan D; Linch DC
Br J Cancer; 1999 Oct; 81(3):476-83. PubMed ID: 10507773
[TBL] [Abstract][Full Text] [Related]
14. Hybrid chemotherapy consisting of cyclophosphamide, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, and vinblastine (C-MOPP/ABV) as first-line treatment for patients with advanced Hodgkin disease.
Montoto S; Camós M; López-Guillermo A; Bosch F; Cervantes F; Blandé J; Esteve J; Cobo F; Nomdedeu B; Campo E; Montserrat E
Cancer; 2000 May; 88(9):2142-8. PubMed ID: 10813727
[TBL] [Abstract][Full Text] [Related]
15. Fifteen-year secondary leukaemia risk observed in 761 patients with Hodgkin's disease prospectively treated by MOPP or ABVD chemotherapy plus high-dose irradiation.
Delwail V; Jais JP; Colonna P; Andrieu JM
Br J Haematol; 2002 Jul; 118(1):189-94. PubMed ID: 12100147
[TBL] [Abstract][Full Text] [Related]
16. Relapse and late complications in early-stage Hodgkin's disease patients with mediastinal involvement treated with radiotherapy alone or plus one cycle of ABVD.
Enrici RM; Anselmo AP; Donato V; Falchetto Osti M; Santoro M; Tombolini V; Mandelli F
Haematologica; 1999 Oct; 84(10):917-23. PubMed ID: 10509040
[TBL] [Abstract][Full Text] [Related]
17. An update on the Vancouver experience in the management of advanced Hodgkin's disease treated with the MOPP/ABV Hybrid program.
Klimo P; Connors JM
Semin Hematol; 1988 Apr; 25(2 Suppl 2):34-40. PubMed ID: 2456621
[TBL] [Abstract][Full Text] [Related]
18. Combination chemotherapy with alternating MOPP-ABVD in advanced Hodgkin's disease.
Brusamolino E; Lazzarino M; Morra E; Inverardi D; Merante S; Castelli G; Canevari A; Dornini G; Bernasconi C
Haematologica; 1989; 74(2):173-9. PubMed ID: 2473013
[TBL] [Abstract][Full Text] [Related]
19. Low O6-alkylguanine DNA alkyltransferase activity in the peripheral blood lymphocytes of patients with therapy-related acute nonlymphocytic leukemia.
Sagher D; Karrison T; Schwartz JL; Larson R; Meier P; Strauss B
Cancer Res; 1988 Jun; 48(11):3084-9. PubMed ID: 2452685
[TBL] [Abstract][Full Text] [Related]
20. Hodgkin's disease, splenectomy and secondary leukemia.
Centurioni R; Brianzoni F; Leoni P; Danieli G
Haematologica; 1993; 78(4):258-9. PubMed ID: 8294062
[No Abstract] [Full Text] [Related]
[Next] [New Search]
